{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:11:56Z","timestamp":1790161916796,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,6]],"date-time":"2017-04-06T00:00:00Z","timestamp":1491436800000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.ctrv.2017.03.006","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T06:17:34Z","timestamp":1490854654000},"page":"181-189","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy"],"prefix":"10.1016","volume":"55","author":[{"given":"Tony S.K.","family":"Mok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucio","family":"Crino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enriqueta","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"De Pas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.W.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Q.M.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2017.03.006_b0005","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1634\/theoncologist.2012-0311","article-title":"Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology","volume":"17","author":"Ou","year":"2012","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2017.03.006_b0010","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.03.006_b0015","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2017.03.006_b0020","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.cell.2007.11.025","article-title":"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer","volume":"131","author":"Rikova","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2017.03.006_b0025","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2017.03.006_b0030","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.ejca.2010.04.002","article-title":"The biology and treatment of EML4-ALK non-small cell lung cancer","volume":"46","author":"Sasaki","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2017.03.006_b0035","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fonc.2014.00182","article-title":"Non-small cell lung carcinoma biomarker testing: the pathologist's perspective","volume":"4","author":"Brega","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0040","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/JTO.0b013e31815e8b60","article-title":"EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers","volume":"3","author":"Inamura","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0045","doi-asserted-by":"crossref","first-page":"5682","DOI":"10.1158\/1078-0432.CCR-11-2947","article-title":"A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer","volume":"18","author":"Soda","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.03.006_b0050","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/cncr.24181","article-title":"The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS","volume":"115","author":"Wong","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2017.03.006_b0055","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.03.006_b0060","unstructured":"Xalkorki (crizotinib) [prescribing information]. New York, NY, USA: Pfizer; 2015."},{"key":"10.1016\/j.ctrv.2017.03.006_b0065","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(12)70344-3","article-title":"Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study","volume":"13","author":"Camidge","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0070","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.03.006_b0075","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.03.006_b0080","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-11-2906","article-title":"Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer","volume":"18","author":"Doebele","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2017.03.006_b0085","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1073\/pnas.1019559108","article-title":"Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK","volume":"108","author":"Katayama","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ctrv.2017.03.006_b0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2017.03.006_b0095","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/annonc\/mdt572","article-title":"Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC","volume":"25","author":"Ou","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0100","doi-asserted-by":"crossref","first-page":"e443","DOI":"10.1200\/JCO.2010.34.1313","article-title":"CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib","volume":"29","author":"Costa","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0105","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.4161\/cbt.22255","article-title":"Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?","volume":"13","author":"Chun","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ctrv.2017.03.006_b0110","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0115","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3389\/fonc.2014.00174","article-title":"A systemic review of resistance mechanisms and ongoing clinical trials in ALK-rearranged non-small cell lung cancer","volume":"4","author":"Esfahani","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0120","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa1007478","article-title":"EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors","volume":"363","author":"Choi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.03.006_b0125","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/JTO.0b013e318287c395","article-title":"MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases","volume":"8","author":"Boland","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"suppl.; abstr. 8030","key":"10.1016\/j.ctrv.2017.03.006_b0130","article-title":"A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors","volume":"32","author":"Horn","year":"2014","journal-title":"J Clin Oncol"},{"issue":"suppl.; abstr. 3401","key":"10.1016\/j.ctrv.2017.03.006_b0135","article-title":"Updated results of a first-in-human dose-finding study of the ALK\/EGFR inhibitor AP26113 in patients with advanced malignancies","volume":"49","author":"Camidge","year":"2013","journal-title":"Eur J Cancer"},{"issue":"suppl.; abstr. LB-298","key":"10.1016\/j.ctrv.2017.03.006_b0140","article-title":"AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2017.03.006_b0145","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.1158\/0008-5472.CAN-10-3879","article-title":"Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors","volume":"71","author":"Lovly","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2017.03.006_b0150","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2017.03.006_b0155","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1073\/pnas.1420785112","article-title":"PF-06463922 is a potent and selective next-generation ROS1\/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations","volume":"112","author":"Zou","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"issue":"suppl.; abstr. 8018","key":"10.1016\/j.ctrv.2017.03.006_b0160","article-title":"Clinical activity and safety of the ALK\/ROS TK inhibitor PF-06463922 in advanced NSCLC","volume":"33","author":"Shaw","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl.; abstr.","key":"10.1016\/j.ctrv.2017.03.006_b0165","article-title":"ORAL33.06 Brigatinib (AP26113) efficacy and safety in ALK+ NSCLC: phase 1\/2 trial results","volume":"10","author":"Gettinger","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0170","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.canlet.2014.05.020","article-title":"Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance","volume":"351","author":"Kodama","year":"2014","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2017.03.006_b0175","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ccr.2011.04.004","article-title":"CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant","volume":"19","author":"Sakamoto","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2017.03.006_b0180","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","article-title":"CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1\u20132 study","volume":"14","author":"Seto","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0185","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1470-2045(14)70362-6","article-title":"Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1\/2 study","volume":"15","author":"Gadgeel","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0190","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1200\/JCO.2015.63.9443","article-title":"Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study","volume":"34","author":"Ou","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0195","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(15)00488-X","article-title":"Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial","volume":"17","author":"Shaw","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0200","unstructured":"Zykadia (ceritinib) [prescribing information]. East Hanover, NJ, USA: Novartis; 2015."},{"key":"10.1016\/j.ctrv.2017.03.006_b0205","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1311107","article-title":"Ceritinib in ALK-rearranged non-small-cell lung cancer","volume":"370","author":"Shaw","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2017.03.006_b0210","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1021\/jm400402q","volume":"56","author":"Marsilje","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2017.03.006_b0215","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2017.03.006_b0220","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1021\/jm2007613","article-title":"Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)","volume":"54","author":"Cui","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2017.03.006_b0225","first-page":"559","article-title":"Effects of meal type of the oral bioavailability of the ALK inhibitor, ceritinib, in healthy adult subjects","volume":"56","author":"Lau","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0230","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Intracranial and whole-body response of ceritinib in ALK inhibitor-na\u00efve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"issue":"suppl.; abstr. 8059","key":"10.1016\/j.ctrv.2017.03.006_b0235","article-title":"A single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ)","volume":"33","author":"Mok","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl.; abstr. 8060","key":"10.1016\/j.ctrv.2017.03.006_b0240","article-title":"ASCEND-3: a single-arm, open-label, multicenter phase II study of ceritinib in ALKi-na\u00efve adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLS)","volume":"33","author":"Felip","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0245","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3747\/co.21.1740","article-title":"Managing treatment-related adverse events associated with Alk inhibitors","volume":"21","author":"Rothenstein","year":"2014","journal-title":"Curr Oncol"},{"issue":"suppl.; abstr. 1764","key":"10.1016\/j.ctrv.2017.03.006_b0250","article-title":"Proactive management of potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK+ NSCLC","volume":"33","author":"Schaefer","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0255","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0260","unstructured":"Bauer TM. Clinical Activity and Safety of the ALK\/ROS1 TK Inhibitor PF-06463922 in Advanced NSCLC. International Association for the Study of Lung Cancer 2015. Oral presentation: Oral 10 SCLC."},{"key":"10.1016\/j.ctrv.2017.03.006_b0265","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1158\/1078-0432.CCR-14-3009","article-title":"Progression-free and overall survival in ALK-positive NSCLC patients treated with sequential crizotinib and ceritinib","volume":"21","author":"Gainor","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"suppl.; abstr. 8058","key":"10.1016\/j.ctrv.2017.03.006_b0270","article-title":"Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-na\u00efve anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): an adjusted indirect comparison","volume":"33","author":"Tan","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2017.03.006_b0275","doi-asserted-by":"crossref","unstructured":"Alectinib Approved for ALK+ Lung Cancer. Cancer Discov 2016;6:115.","DOI":"10.1158\/2159-8290.CD-NB2016-001"},{"key":"10.1016\/j.ctrv.2017.03.006_b0280","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1753465815617871","article-title":"Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches","volume":"10","author":"Shea","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.ctrv.2017.03.006_b0285","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4172\/2161-0398.1000108","article-title":"Recent advances in molecular targeted therapy for advanced colorectal cancer and non\u2013small cell lung cancer","volume":"02","author":"Tanaka","year":"2012","journal-title":"J Phys Chem Biophys"},{"key":"10.1016\/j.ctrv.2017.03.006_b0290","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.ctrv.2017.03.006_b0295","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.apsb.2014.12.007","article-title":"Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance","volume":"5","author":"Song","year":"2015","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.ctrv.2017.03.006_b0300","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2217\/fon.14.94","article-title":"Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer","volume":"10","author":"Vansteenkiste","year":"2014","journal-title":"Future Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217300439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737217300439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T04:48:29Z","timestamp":1656391709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737217300439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":60,"alternative-id":["S0305737217300439"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.03.006","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2017.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}